FY2025 · ended Dec 31, 2025 · Revenue $23.34M, +28.7% YoY · Filed Mar 20, 2026
DataMeds AI, Inc. (MEDS) files with the SEC under industry code 5122, Wholesale-Drugs, Proprietaries & Druggists' Sundries. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $23.3 million and a net loss of $101.3 million. As of Jun 30, 2026 it held $2.5 million in cash and investments and $32.7 million in total debt.
Revenue (TTM)
$8.02M
Net income (TTM)
$-88.28M
Operating cash flow (TTM)
$-13.74M
Free cash flow
—
EPS (TTM)
$-1.23
Dividend per share
None
Shares outstanding
104.87M
+101.9% vs prior year
Net cash
$-30.20M
as of Jun 30, 2026
Operating margin
-875.7%
FY 2026
Company profile
- Industry
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (SIC 5122)
- Listed as
- MEDS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Tampa, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2030763
- Former names
- Wellgistics Health, Inc. (until Jul 21, 2026); Danam Health, Inc (until Sep 27, 2024)
Other Wholesale-Drugs, Proprietaries & Druggists' Sundries companies
- Mckesson Corp MCK
- Cencora, Inc. COR
- Cardinal Health Inc CAH
- Herbalife Ltd. HLF
- Nu Skin Enterprises, Inc. NUS
- EnerSyn Global Inc. ESYN
- Cosmos Health Inc. COSM
- Cellyan Biotechnology Co., Ltd HKPD
All 11 Wholesale-Drugs, Proprietaries & Druggists' Sundries companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Revenue | $23.3M | $18.1M |
| Operating income | -$93.7M | -$6.1M |
| Net income | -$101.3M | -$6.9M |
| Diluted EPS | -$1.43 | -$0.15 |
| Operating cash flow | -$10.9M | -$1.2M |
| Total assets | $30.5M | $57.3M |
| Total liabilities | $42.9M | $50.6M |
| Stockholders' equity | -$12.4M | $6.7M |
| Cash and investments | $42,571 | $1.0M |
| Total debt | $24.7M | $25.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Agreement ended, Regulation FD disclosure
|
Nov 5, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 26, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 20, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Material agreement, Listing notice, Unregistered share sale
|
Oct 16, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Other events
|
Oct 13, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Other events
|
Sep 17, 2026 | Sep 11, 2026 |
All 176 DataMeds AI, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.